Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia.
Expert Rev Clin Immunol. 2015 Aug;11(8):921-933
Authors: Hoffman TW, van Kessel DA, van Velzen-Blad H, Grutters JC, Rijkers GT
Abstract
Antibody replacement therapy has been used in the treatment of primary antibody deficiencies (PADs) for several decades, and an evidence-based guideline for its treatment is currently available. By contrast, the use of antibody replacement therapy in iatrogenic hypogammaglobulinemia (IHG), a condition that is associated with immunosuppressive medication, has hardly any evidence base and no guidelines. As IHG can be equally as severe as PAD and is much more prevalent, evidence-based guidelines are urgently needed. This review will focus on the differences and similarities between PAD and IHG and the use of antibody replacement therapy in both conditions. Suggestions for the development of evidence-based guidelines and future research are given.
PMID: 26181342 [PubMed – as supplied by publisher]
Powered by WPeMatico